Genenta Science S.p.A. (GNTA)

USD 5.15

(-2.83%)

Market Cap (In USD)

94.19 Million

Revenue (In USD)

-

Net Income (In USD)

-11.64 Million

Avg. Volume

13.21 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
2.2-7.28
PE
-
EPS
-
Beta Value
0.741
ISIN
US36870W1009
CUSIP
36870W100
CIK
1838716
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Pierluigi Paracchi
Employee Count
-
Website
https://www.genenta.com
Ipo Date
2021-12-15
Details
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company's lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. It is also developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. The company was incorporated in 2014 and is headquartered in Milan, Italy.